Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30325623 | 1.00 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL25201032 | 1.00 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2301080 | 1.00 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL26607392 | 1.00 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2670204 | 0.86 | MEN1 (0.35) | MEN1MAPK1KMT2AGAABTK | |
| SCHEMBL4748874 | 0.86 | MEN1 (0.37) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2670376 | 0.86 | MEN1 (0.37) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL4918795 | 0.85 | MEN1 (0.38) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2670103 | 0.85 | MEN1 (0.38) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL7517321 | 0.85 | PSEN1 (0.35) | MEN1MAPK1KMT2AGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368192-A1 | Nitrogen-Containing Heterocyclic Compound, and Preparation Method Therefor, Intermediate Thereof, and Application Thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-17 | — | — | US | disclosed |
| EP-4365178-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | Shanghai Allist Pharmaceuticals Co., Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| EP-3863713-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | MEN1 2711/4885MAPK1 2675/4885KMT2A 1974/4885 |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | MEN1 1908/4885MAPK1 1420/4885KMT2A 1389/4885 |
| US-20240368192-A1 | Nitrogen-Containing Heterocyclic Compound, and Preparation Method Therefor, Intermediate Thereof, and Application Thereof | KRAS, NRAS, HRAS | MEN1 151/4885MAPK1 962/4885KMT2A 3431/4885 |
| US-12091399-B2 | Phenyltetrazole derivatives as plasma kallikrein inhibitors | KLKB1, SERPINE1, SERPINB1 | MEN1 1908/4885MAPK1 1420/4885KMT2A 1389/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | MEN1 2711/4885MAPK1 2675/4885KMT2A 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.